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Annexin I has been proposed to inhibit phospholipasc A2 by direct interaction through a specific amino acid sequence spanning residues 246-254. 
The possible role of this region was investigated by protcin engineering. Three point mutations and a deletion have been performed. The four mutant 
proteins have been expressed in E. cnli, purified and rested for calcium and lipid binding. and for phospholipase inhibition. All mutant proteins 
, conscrvcd the properties of the wild-type recombinant protein. This result clearly dcmonstratcs that this part of the molecule is not involved in 
the inhibition of phospholipasc AZ. 
Anncxin I: Site-directed mutagenesis: Phospholipase AZ inhibition 
1. INTRODUCTION 
Annexins are a family of proteins known to bind 
acidic phospholipids in a calcium-dependent manner 
[l]. Annexin I (lipocortinl) has been reported to inhibit 
phospholipase A, in vitro [2]. As it is suspected to be 
inducible in some cell lines by glucocorticoids, (al- 
though this observation is largely controversial [3.4]), 
annexin 1 has been proposed to be the mediator of the 
anti-inflammatory effect of these drugs. To test this 
hypothesis some authors initiated very precise studies 
on the kinetics of PLA, inhibition by annexins. The 
insoluble nature of the phospholipid substrate compli- 
cates this kind of studies so that different experimental 
models were developed. Davidson et al. [5] demon- 
strated that the inhibition could be overcome by in- 
creasing the phospholipid substrate concentration, 
suggesting that annexins inhibit PLA? by substrate 
depletion rather than by direct interaction with the en- 
zyme. On the other hand, Miele et al. [6] designed 3 
short synthetic peptides exhibiting potent PLA,-inhibit- 
ing properties in vitro. These nonameric. ol-helical pep- 
tides were deduced from sequence comparison between 
annexin 1 and uteroglobulin. another PLA, inhibitor. 
The authors suggested that the peptides inhibited PLAz 
by direct interaction with the enzyme.This result is not 
easy to reproduce [7], and it strongly depends on the 
assay conditions [8]. These last observations raise the 
question of real significanez of this sequence inside the 
whole molecule of annexin 1. In order to answer this 
question we performed mutations on the specific zone 
corresponding to the peptides. The mutant proteins 
have been produced by genetic engineering, purified 
and checked for PLAz inhibition. 
2. MATERIALS AND METHODS 
A cDNA AgtlO library was constructed using the U937 cell line. 
This library was screened using two oligonuclcotides deduced from the 
published cDNA sequence of human annexin I [9]: GGAATTCTGA- 
‘I’ACCATTGCC (5’ region) and CTCCACAAAGAGCCACCAGG 
(3’ region). Two overlapping clones were obtained and used to rccon- 
struct the complete cDNA with [he common central sitcBgfl1. 
Mutants were constructed using the PCR-mediated method as dc- 
scribed [IO]. by means of 2 oligonuclcotides containing a Ncol site and 
corresponding to the 5’ and 3’ extremities. and a third oligonuclcotide 
containing the rcquircd mutation. The PCR fragment obtained was 
digested and cloned into the Ncol site of pKK233-2 (Pharmacia). The 
mutation and the whole sequence of each clone were verilied by the 
Sanger dideoxy method usingdimerent oligonucleotidcs sprcd over t1:c 
cDNA sequcncc. 
nhl,rerirrriorrs. PLA:. phospholipase A,: PCR. polymcrasc chain rcac- 
tion; PAGE. polyacrylamidc gel clcctrophorcsis. 
Wild type and mutant anncxins were cxprcsscd in E co/i and puri- 
fied from the soluble fraction of the bacterial sonicatc by the liposo- 
mcs-mediated method of Kaplan CI al. [I I]. The liposomcs wcrc com- 
posed of an cquimolar mixture of phosphatidyl scrinc. phosphatidyl 
cthanolaminc and cholesterol. and were ohtaincd as dcscribcd [IZ]. 
The rclativc quantities of the protcins purified in this manner were 
cslimatcd by scanning SDS-PAGE-migrations of each protein using 
a Shimatzu apparatus. 
Correspufrklrce urklrcss: G. TravC. Inscrm U6.S. cast postalc no. 100. 2.4. I’rtrfkrriot,,r of I/W ctrkim ml lipid bi~tflitr~,/r(icritr,t O/ c/y37 &IS 
UnivcrsitC dc Monrpcllicr II. place Eugknc Bataillon, 34095 Montpel- Differcntiatcd U937 cells (results not yet published) wcrc pcllctcd, 
licr Ccdcx 5. Fritncc. then rcsuspcndcd in 5 mM Tris. pH 7.5.0,5 mM EGTA. I mM PMSF 
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at 0°C. This mixture was gently vortexcd to allow only partial disrup- 
tion of the cells. then centrifuged at 30 000 x g. The supernatant was 
then treated exactly like the soluble bacterial fraction in section 2.3. 
2.5 Dose-response tneasurernents of mti-PLA, crctirit_v 
The EGTA eluates from liposomes were tested for PLA, inhibition 
by the method of Rothut et al. [l3]. using [‘HI-labeled E. co/i mem- 
branes as a substrate. The conditions were those described [S] with 
minor modifications: IO pl of substrate and I50 ng of PLA: were used. 
There were controls to test the influence of the EGTA elution buffer 
and of PLAr or inhibitor alone. The inhibition was quantified by the 
following ratio: 
I = [R(S+Pj - R(S+P+I)]/[R(S+P) - R(S)] 
Where R(S) = ‘H cpm released in an assay with substrate alone: 
R(S+P) = ‘H cpm released in an assay with substrate plus phos- 
pholipase; and R(S+P+l)= ‘H cpm released in an assay with substrate 
plus phospholipase plus inhibitor. 
3. RESULTS AN3 DISCUSSION 
b4iele et al. [6] have defined a ‘core’ tetrapeptide Lys- 
Val-Leu-Asp common to all their active peptides. This 
sequence is a fragment of a classical amphipatic o-helix 
with 2 charged residues facing the solvent and 2 hydro- 
phobic residues buried inside the protein. An extrapola- 
tion. by sequence comparison, of the recently published 
cristallographic structure of annexin 5 [14] for annexin 
1 confirms the peripheral position of this helix. In the 
hypothesis of an inhibition mediated by protein-protein 
interaction the 2 charged residues should be extremely 
important since they are exposed to the solvent and they 
are able to engage ionic interactions. We thus per- 
formed the double point mutation Ly’So+Thr, Asp’“‘+ 
Asn. turning the 2 charged residues into neutral but 
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Fig. I. SDS-PAGE migration of the purilicd mutant proteins. The 
mutant proteins were purified from E. coliusing their calcium-dcpcnd- 
cnt liposomc binding propcrtics as dcscribcd in Materials and Met- 
hods. The proteins wcrc analyscd on a 12.5% gel stained with Coomas- 
sic brilliant blue. Each sample corresponds to the quantity obtained 
from I ml of an IPTG-induced E. co/i culture. Lane I, wild-type 
recombinant anncxin I: Ianc 2, mutation (Kzm-tT. D”‘-+N: Ianc 3, 
dclction (N”‘KVLD’“X): lane 4, mutation (Dr”+Y): lane 5. mutation 
polar ones. This mutation allows the removal of the 
charges without affecting the local helical structure. 
Two other point mutations affect the NHI, extremity of 
the sequence described by Miele et al [6]. One is a single 
mutation abolishing a negative charge, AspZ4’+ Asn: 
the other is a double mutation that abolishes the same 
residue but conserves the local charge, Aspz4’+ Gly and 
Asn’49+ Asp. The fourth mutation is a deletion of five 
amino acids, Asn”4’-Lys-Val-Leu-Asp253. Four of 
these constitute the ‘core tetrapeptide’ Lys-Val-Eeu- 
Asp common to uteroglobin, annexin 1, and all the 
active peptides synthesized. If this sequence is really 
involved in PLAZ inhibition, its deletion is expected to 
induce noticeable changes to the activity of annexin 1. 
The 4 mutant proteins, and the wild-type recombi- 
nant protein as a control, were expressed and purified 
on liposomes. As shown in Fig. 1, the 5 proteins were 
recovered in the same yield, indicating that these muta- 
tions affect neither the expression, the stability, nor the 
binding of the protein to lipids and calcium under the 
conditions we used. 
The ability of the different liposome-purified proteins 
to inhibit PLAz was studied by dose-response experi- 
ments using -‘H-labeled E. co/i membranes. To ensure 
that we really measured the activity of recombinant 
annexins and not that of some bacterial contaminant we 
made 2 kinds of controls. As a negative control we 
performed the liposome-mediated calcium-dependent 
extraction on the same bacterial strain containing the 
wild-type expression plasmid pKK233-2 devoid of the 
insertion coding for annexin 1: no PLAz-inhibiting ac- 
tivity was found in the extract. As a positive control the 
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Fig. 2. Dose-rcsponsc of phospholipasc inhibition by the mutant 
proteins. The inhibition values arc calculated from one rcprcsentativc 
cxpcrimcnt as described in Materials and Methods. At lcast 3 expcri- 
mcnts wcrc pcrformcd on diffcrcnt days for each protein. (*) Wild- 
type recombinant anncxin I: (0) mutation (Kzm+T. D’““+N; (v) 
dclction (Nz4Y)KVLDzsJ): (‘I) mutation (Dr”-+ N): (0) mutation 
(DzJ’-r G. Nz’v-tDj. 
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same kind of extraction was performed on differentiat- 
ed U937 cells. We thus obtained a calcium-dependent 
lipid-binding fraction containing the annexin 1 ex- 
pressed in these cells. SDS-PAGE of this fraction show- 
ed 3 major bands between 32 and 35 kDa. As expected, 
this fraction exhibited PLA,-inhibiting activity. For a 
same quantity of protein, estimated by scanning anaiy- 
sis of the gel. the bacteria] extract was found to be three 
time more active than the cellular extract. This is a 
logical result considering that annexin 1. as shown by 
electrophoresis. should represent only 30% of the ex- 
tract since it is contaminated by other proteins which 
are not all phospholipase inhibitors. 
Unexpectedly. the profiles we observed are identical 
for the 4 mutant proteins and the bacterial control (Fig. 
2). This result unambiguously indicates that the differ- 
ent mutations we made on the inhibitor Feptidc.:,i;liatcd 
sequence have no effect on the in vitro inhibition of 
PLA2 by annexin 1.. If this region was (even partly) 
implicated we might have noticed some modifications. 
The fact that the deleted mutant proteins conserve the 
intact properties of the wild-type protein specifically 
argues against an inhibition by contact through this 
zone as was suggested by Miele et al. [6]. On the other 
hand, our results could be explained by the substrate- 
depletion hypothesis. since no other interacting region 
has yet been proposed. Another interesting point is how 
the peptide itself inhibits PLA, in some in vitro and in 
vivo assays. Newman et a]. [8] recently demonstrated 
that the ability of the synthesized peptides to inhibit 
PLA? was linked to their capacity to penetrate the lipid 
monolayer. One must keep in mind that all the residues 
of a peptide are able to engage interactions, although 
the same sequence included inside a protein has only a 
few residues exposed. In the synthesized peptides. the 
hydrophobic residues (which are buried in annexin 1). 
are probably involved in the penetration of the lipid 
monolayer and perhaps in some perturbations of the 
interaction PLA,/substrate. To check this possibility 
further experiments can be carried out such as testing 
the PLA,-inhibiting ability of other amphipathic pep- 
tides. 
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